(Q38526870)

3 September 2017

1 reference

title

Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus (English)

1 reference

3 September 2017

1 reference

Yahiya Y Syed

1

1 reference

3 September 2017

Paul L McCormack

series ordinal

2

1 reference

3 September 2017

publication date

1 July 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

75

1 reference

3 September 2017

issue

10

1 reference

3 September 2017

page(s)

1141-1152

1 reference

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

AACE comprehensive diabetes management algorithm 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Unraveling the science of incretin biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Exenatide extended-release: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noni

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0420-Z

Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes

21 January 2018

1 reference

12 December 2020

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

1 reference

12 December 2020

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.

1 reference

12 December 2020

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment

1 reference

12 December 2020

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

1 reference

12 December 2020

10.1007/S40265-015-0420-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1025377362

0 references

1 reference